GoodRx the leading prescription savings platform in the United States, has announced the appointment of Christopher A. McGinnis as its new Chief Financial Officer (CFO), effective February 4, 2025. McGinnis, a seasoned financial executive with three decades of experience in…
Announces Cencora Reports Strong Fiscal 2025 First Quarter Results, Expects Continued Growth and Strategic Expansion Announces Cencora has announced its results for the first quarter of fiscal year 2025, reporting robust growth and strategic expansion despite challenges in some market…
Medications from Miist Therapeutics Secures $7M in Funding to Develop Fast-Acting Treatments Medications Miist Therapeutics, a trailblazing company focused on the development of physics-based inhaled medicines, has announced that it has secured $7 million in seed funding from a group…
LEO Pharma Reports Positive DELTA TEEN Results for Anzupgo® in Adolescent CHE LEO Pharma Reports A/S, a global leader in medical dermatology, has announced the successful completion of its DELTA TEEN trial, a pivotal phase 3 clinical study evaluating Anzupgo®…
Tonix Pharmaceuticals Appoints Siobhan Fogarty as Chief Technical Officer Tonix Pharmaceuticals Holding a fully integrated biopharmaceutical company specializing in the development and commercialization of innovative therapies for pain management and other health challenges, has announced the promotion of Siobhan Fogarty…
Enveric Biosciences Completes $5 Million Public Offering Enveric Biosciences a leading biotechnology company focused on the development of groundbreaking neuroplastogenic small-molecule therapeutics, has made a significant advancement in its efforts to address some of the most pressing challenges in mental…
AdvanCell Closes Oversubscribed $112M Series C Funding AdvanCell, a pioneering clinical-stage radiopharmaceutical company focused on developing groundbreaking cancer therapeutics, has announced the successful closure of an oversubscribed US$112 million Series C financing round. This significant milestone highlights the confidence investors…
Sionna Therapeutics Announces $150M IPO to Advance Cystic Fibrosis Drug Development Sionna Therapeutics, a Massachusetts-based biotechnology company specializing in cystic fibrosis (CF) treatments, has officially announced the terms of its highly anticipated initial public offering (IPO). The company aims to…
Galderma’s Breakthrough Findings Galderma (SWX:GALD), a global leader in dermatology, has announced the results of its Phase IIIb RELAX clinical trial, demonstrating the rapid onset, long-lasting efficacy, and high patient satisfaction of RelabotulinumtoxinA (Relfydess™) for treating frown lines (glabellar lines).…
KORU Medical Systems Partners on Phase III Trial for Rare Renal Disorder Treatment, Expanding Its Reach in Subcutaneous Infusion Solutions KORU Medical Systems (NASDAQ: KRMD), a leading innovator in large-volume subcutaneous infusion solutions, has announced an exciting collaboration with a…
Ferrer Achieves Compliance Leader Verification™: A Testament to Excellence in Ethics and Corporate Responsibility In a significant milestone for ethical business practices, Ferrer, a global pharmaceutical company headquartered in Barcelona, has been awarded the prestigious Compliance Leader Verification™ by Ethisphere,…
Lead Capital Partners and Petra Capital Partners Propel Lieberman’s Growth with Strategic Platform Investment In a landmark move set to bolster its position as a leader in primary market research, Lieberman, Inc., a premier research and analytics firm, has secured…